¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå(-2035³â) : ¾à¹° Á¾·ù(mAbs, GCSF, Àν¶¸°, Ç×ÀÀ°íÁ¦, rhGH, Å׸®ÆÄ¶óŸÀ̵å, GLP-1), ÀûÀÀÁõ, °æÀï ±¸µµ, Áö¿ªº°
Biosimilars Market by Drug Class (mAbs, GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication, Competitive Landscape, Region - Global Forecast to 2035
»óǰÄÚµå : 1754853
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 392 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,767,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,091,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,141,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,671,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ±Ô¸ð´Â 2025³â 350¾ï 4,000¸¸ ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È CAGR 7.5%·Î ¼ºÀåÇÏ¿© 2035³â¿¡´Â 722¾ï 9,000¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ¼ºÀå¿¡´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç°ÀÇ ¾ÈÀü¼º, À¯È¿¼º, ȣȯ¼º¿¡ ´ëÇÑ Àνİú ±³À°ÀÌ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²ÀûÀÎ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í °ø°ø ¹× ¹Î°£ ÀÇ·áºñ ÁöºÒÀÚ°¡ ½ÃÇàÇÏ´Â À¯¸®ÇÑ º¸Çè Àû¿ë ¹× »óȯ ü°è°¡ ÀÌ·¯ÇÑ ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ½ÃÀåÀº Á¦Á¶ °øÁ¤ÀÇ º¹À⼺ ¹× °æÀï ½ÉÈ­¶ó´Â µµÀü¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, °¡°Ý Ãø¸éÀÇ Å« ¾Ð·ÂÀº Ãß°¡ÀûÀÎ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2032³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2035³â
´ÜÀ§ ±Ý¾×(´Þ·¯)
ºÎ¹® ¾à¹° Á¾·ù¡¤ÀûÀÀÁõ¡¤Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

´ÜŬ·ÐÇ×ü ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÎÇø¯½Ã¸¿, ¸®Åö½Ã¸¿, ¾Æ´Þ¸®¹«¸¿, Æ®¶ó½ºÅõÁÖ¸¿, Æèºê·Ñ¸®ÁÖ¸¿, µàÇʷ縿, ¿ì½ºÅ×Ű´©¸¿, ¸®»êŰÁÖ¸¿°ú °°Àº ´ÜŬ·ÐÇ×ü(mAb)´Â ÀÚ°¡¸é¿ªÁúȯ, °¢Á¾ ¾Ï, ¸¸¼ºÁúȯ, ƯÁ¤ °¨¿°ÁúȯÀÇ Ä¡·á¿¡ ÁÖ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ ¼ö Áõ°¡, mAbÀÇ Ã¤Å÷ü Áõ°¡, ÁÖ¿ä ¹ÙÀÌ¿ÀÀǾàǰÀÇ Æ¯Çã ¸¸·á°¡ ÀÓ¹ÚÇÔ¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¼ö¿ä´Â ÇâÈÄ ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̵é Ä¡·áÁ¦´Â ¾Ï, ·ù¸¶Æ¼½º °üÀý¿°, °Ç¼±, ¿°Áõ¼º ÀåÁúȯ µî ¸¸¼ºÀûÀÌ°í »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀÇ °ü¸®¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, À̵é ÁúȯÀº °í·ÉÈ­¿Í »ýȰ½À°ü À§Çè¿äÀÎÀÇ Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, mAb ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀåÀº ÀÇ·áºñ Àý°¨°ú Ä¡·á Á¢±Ù¼º Çâ»ó¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇâÈÄ 10³â À̳»¿¡ 10-15°³ÀÇ ÁÖ¿ä mAb°¡ ƯÇã°¡ ¸¸·áµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °æÀïÀÌ ½ÉÈ­µÉ °ÍÀ¸·Î ¿¹»óµÇ¾î Á¦¾à»çµéÀÇ °ü½ÉÀÌ ÀÌ ½ÃÀå¿¡ ÁýÁߵǰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Ï ¹× ÀÚ°¡¸é¿ªÄ¡·á ºÐ¾ß¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ Àú·ÅÇÑ °¡°Ý°ú Æø³ÐÀº ÀûÀÀÁõÀÌ ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ÀÇ ±Þ°ÝÇÑ ¼ºÀåÀº ÀϺΠºí·Ï¹ö½ºÅÍ ¹ÙÀÌ¿ÀÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÈ °Í°ú BPCIA(Biologics Price Competition and Innovation Act)¿¡ ÀÇÇØ È®¸³µÈ ±ÔÁ¦ ȯ°æÀÌ Á¡Á¡ ´õ À¯¸®ÇØÁö°í ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇâÈÄ 10³â°£ ¹Ì±¹¿¡¼­´Â ŰƮ·ç´Ù(Æèºê·Ñ¸®ÁÖ¸¿), ½ºÅÚ¶ó¶ó(¿ì½ºÅ×Ű´©¸¿), ¿¡ÀÌ·¹¾Æ(¾ÆÇø®¹ö¼ÁÆ®) µî ¼ö½Ê¾ï ´Þ·¯ ±Ô¸ðÀÇ ÁÖ¿ä »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ Ãâ½ÃµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ƯÈ÷ ¾Ï, ¸é¿ª, ¾È°ú ºÐ¾ß¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÌ ´Ù·ê ¼ö ÀÖ´Â ½ÃÀåÀ» Å©°Ô È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ÁöºÒÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ º¸±ÞÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ±â¼ú¡¤Æ¯Çã µ¿Çâ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ±ÔÁ¦ ¹× ¸®º£ÀÌÆ® ȯ°æ, »ç·Ê ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÁ¤ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°¡¤Áö¿ªº°¡¤ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ¾à¹° Á¾·ùº°

Á¦7Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ÀûÀÀÁõº°

Á¦8Àå ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

Á¦11Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global biosimilars market is projected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period. The expansion of the biosimilars market has been predominantly fueled by heightened awareness and education regarding the safety, efficacy, and interchangeability of biosimilar products. Additionally, favorable insurance coverage and reimbursement structures implemented by both public and private payers have played a crucial role in this growth, alongside an increasing demand for cost-effective biologic therapies. Nonetheless, the market faces challenges from escalating complexities in the manufacturing processes and intensifying competition, leading to significant pricing pressures that may hinder further growth.

Scope of the Report
Years Considered for the Study2024-2032
Base Year2024
Forecast Period2024-2035
Units ConsideredValue (USD billion)
SegmentsDrug Class, Indication, Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The monoclonal antibodies segment is expected to grow at the highest CAGR during the study period.

Monoclonal antibodies (mAbs) such as infliximab, rituximab, adalimumab, trastuzumab, pembrolizumab, dupilumab, Ustekinumab, Risankizumab, and others are primarily utilized for the treatment of autoimmune disorders, various cancers, chronic illnesses, and select infectious diseases. The anticipated rise in patient demographics, coupled with increasing adoption rates and the impending patent expirations of several key biologics, is projected to drive demand in the mAb sector. These therapeutics are extensively employed in managing chronic and life-threatening conditions, notably cancer, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which are experiencing heightened global prevalence due to an aging populace and lifestyle-related risk factors. The emergence of biosimilars for these mAbs offers an opportunity to mitigate healthcare expenditures and improve access to essential therapies. With over 10-15 leading mAbs facing patent expirations within the next decade, competition is poised to intensify, piquing the interest of pharmaceutical companies in the mAb market. The affordability and extensive applicability of mAb biosimilars, particularly in oncology and autoimmune therapies, are likely to significantly contribute to future market growth.

The US is expected to grow at the highest CAGR in the global biosimilars market from 2025 to 2035.

The United States is projected to experience the highest compound annual growth rate (CAGR) in the global biosimilars market between 2025 and 2035. This rapid growth is largely driven by the expiration of patents on several blockbuster biologics and the increasingly favorable regulatory environment established by the Biologics Price Competition and Innovation Act (BPCIA). Over the next decade, the US is expected to see biosimilar entries for major biologics such as Keytruda (pembrolizumab), Stelara (ustekinumab), and Eylea (aflibercept), which are all multi-billion-dollar products. These launches will significantly expand the addressable market for biosimilars, particularly in oncology, immunology, and ophthalmology. Additionally, the growing payer and provider acceptance of biosimilars in the US healthcare system is accelerating uptake. For instance, biosimilars of adalimumab (Humira), the highest-selling biologic in the US for over a decade, began launching in 2023 with multiple entrants such as Amgen, Boehringer Ingelheim, and Sandoz. Early signs show that competitive pricing is starting to drive formulary access and payer adoption. Moreover, legislative and policy efforts, including Medicare reforms and price transparency regulations, are expected to further incentivize biosimilar use, leading to cost savings and greater market penetration. As more biosimilars gain interchangeable status, market dynamics are likely to mirror those seen in generics, thus supporting sustained growth in the US biosimilars sector over the next decade.

The primary interviews conducted for this report can be categorized as follows:

List of Key Companies Profiled in the Report:

Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion, Inc. (South Korea), Biocon (India), Dr. Reddy's Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), STADA Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Biologics Co., Ltd. (South Korea), Amneal Pharmaceuticals LLC (US), Coherus BioSciences, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biopharmaceuticals, Inc. (China).

Research Coverage:

This research report categorizes the biosimilars market by biosimilars market, by drug class [monoclonal antibodies (rituximab, infliximab, adalimumab, trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, and other monoclonal antibodies), granulocyte colony-stimulating factor, insulin, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, anticoagulants, Aflibercept, GLP-1 antagonist, and other products), By indication (oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, type II diabetes, obesity, and other indications) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimilars market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the biosimilars market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 BIOSIMILARS MARKET, BY DRUG CLASS

7 BIOSIMILARS MARKET, BY INDICATION

8 BIOSIMILARS MARKET, BY REGION

9 COMPETITIVE LANDSCAPE

10 COMPANY PROFILES

11 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â